Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Trial Profile

A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel trevatide (Primary) ; Trastuzumab
  • Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; HER2 positive breast cancer; Meningeal carcinomatosis
  • Focus Therapeutic Use
  • Acronyms GRABM-B
  • Sponsors AngioChem
  • Most Recent Events

    • 22 Jan 2020 Results assessing efficacy of ANG1005 in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases, published in the Clinical Cancer Research.
    • 03 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2015 Results of a biomarker sub-study (n=10) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top